FDA's Draft Guidance for Process Validation: Can It Be Applied Universally?5

Others made similar observations, and the general thrust of the comments on the proposed change was that the presently available tools to control aseptic processing do not constitute adequate confirmation to be considered validation. The arguments against the proposed revision notwithstanding, FDA made the change to the regulation. The arguments presented above were deemed inadequate, though no clear rationale or supportive scientific evidence to the contrary was offered. In the context of this larger document, the earlier objections to FDA's CGMP revision and its relevance to this draft guidance have perhaps been made clearer, and the specific difficulties more evident.
FDA indicated that media fills, environmental monitoring, routine processing controls, and satisfactory sterility tests constituted a validation in principle if not in fact (12). That position is inconsistent with the concepts presented in the draft validation guidance, which requires substantially more robust evidence of the link between input and results. The difference may seem on one level to be semantic, yet a gulf nevertheless exists between the industry's and regulators' positions with respect to validation of aseptic processing. Regardless of how one views this conundrum, one point should cause little or no confusion: the statistical component of the guidance really doesn't work with respect to linking any process parameters directly to performance.
Manual processes. Operators' skills and proficiency play a major role in the outcome of a substantial number of important pharmaceutical processes such as manual sanitization of equipment and environments and aseptic gowning. In addition, the operator's abilities may sometimes negate other controls that are present. Processes that rely heavily on operator proficiency may not be considered adequately validated, regardless of the outcome. These processes include manual cleaning, wet granulation, sugar coating, and manual inspection. It is hard to conceive that any of these could attain the level of control associated with validation. These processes are likely best considered as verified, given their heavy dependence on the operator.
A final perspectiveA substantial amount of clarification, and perhaps broader interpretation, is needed to reconcile the draft guidance with the elements of pharmaceutical validation that do not directly result in the preparation of an intermediate material, drug substance, or drug product. In some situations, the draft guidance certainly can be used without change, but a degree of caution is necessary. Recommendations for a life-cycle approach are certainly acceptable; many pharmaceutical firms had already instituted comparable programs. It seems that the less the particular process results in or influences a material that can be analyzed or is subject to operator variability, the less useful the statistical elements of the guidance are. Without parameters and attributes that are readily quantifiable, using statistics is certainly inappropriate. The design and development experimental evidence works quite well in some instances but appears to be a force fit in other applications, largely according to whether the process outcome is numeric. Successfully linking design and development and initial and ongoing qualification for these processes also seems to depend on the extent to which process success is readily quantifiable.
The qualification and validation model provided in the draft guidance appears fully applicable to validation of products and processes but only partially applicable in other areas. Its usefulness for sterilization and aseptic processing, two of the more important pharmaceutical processes, is highly questionable. An extensive effort to provide a common level of expectations between FDA and industry (as well as within FDA and industry) is urgently needed to clarify how implementation is to be addressed. For sterile products, where FDA theory and industry practice are most divergent, an update of FDA's 1994 Guidance Submission for Sterile Products might be the best way to accommodate the desired approach with current methods for validation (13). 
Conclusion
The draft guidance about process validation is refreshingly simple and supports good science, yet it is demanding with respect to the level of effort required to properly validate a pharmaceutical production process. The variety of approaches that the pharmaceutical industry uses for process validation extends from the merely cosmetic, providing little if any real support to product quality, to overblown efforts that have nearly crippled firms with their complexity and restrictive approach. The draft guidance is not perfect, and improvement and clarification are certainly necessary, especially regarding the guidance's application to sterile products. The guidance requires a restructuring of validation programs to tie development science more closely to commercial-scale manufacturing. It clarifies FDA expectations for validation in a more coherent manner than previous documents. The expectation for life-cycle treatment with heavy statistical emphasis mandates that sound science be applied to validation more clearly than ever before.
For applications in the validation of processes and products that result from them, the author commends those who prepared the guidance for a job well done. It is essential, however, that FDA and industry proceed with special caution in the areas reviewed above because blind adherence to the concepts of the draft guidance will likely lead many astray.
James Agalloco is the president of Agalloco and Associates, PO Box 899, Belle Mead, NJ 08502, tel. 908.874.7558, References
1. FDA, Draft Guidance for Industry—Process Validation: General Principles and Practices (Rockville, MD, Nov. 2008).
2. J. Agalloco, "The Validation Life Cycle," J. Parenter. Sci. Technol. 47 (3), 142–147 (1993).
3. K. Chapman, "The PAR Approach to Process Validation," Pharm. Technol. 8 (12), 24–36 (1984).
4. R.E. Madsen, "Real Compliance and How to Achieve It," PDA J. Pharm. Sci. Technol. 55 (2), 59–64 (2001).
5. Code of Federal Regulations, Title 21, Food and Drugs (General Services Administration, Washington, DC, September 2008), Part 211, pp. 51919–51933.
6. FDA, "Pharmaceutical CGMPs for the 21st Century—A Risk-Based Approach," Final Report (Rockville, MD, Sept. 2004).
7. ASTM, "E 2500-07 Standard Guide for Specification, Design, and Verification of Pharmaceutical and Biopharmaceutical Manufacturing Systems and Equipment," (ASTM, West Conshohocken, PA, 2007).
8. J. Agalloco, "Compliance Risk Management: Using a Top Down Validation Approach," Pharm. Technol. 32 (7), 70–78 (2008).
9. J. Harris et al., "Validation Concepts for Computer Systems Used in the Manufacture of Drug Products," in Proceedings: Concepts and Principles for the Validation of Computer Systems in the Manufacture and Control of Drug Products (Pharmaceutical Manufacturers Association, Chicago, 1986).
10. PDA, "Process Simulation Testing for Aseptically Filled Products, PDA Technical Report #22," PDA J. Pharm. Sci. Technol. 50 (6), supplement (1996).
11. J. Agalloco, Comments to FDA, submitted Feb. 5, 2008, Docket No. 2007N-0280.
12. Federal Register, 73 (174), pp. 51919–51933, Sept 8, 2008.
13. FDA, Guidance for Industry for the Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products (Rockville, MD, Nov. 1994)

2 comments:

prabhakar yadav said...

Biopharmaceutical products processing conventional of instruments. Biopharmaceutical systems as well as disposable, single-use systems. Biopharmaceutical products are manufacture and provide to suppliers around the globe.

sanjaya dash said...

The draft guidance is not perfect, and improvement and clarification are certainly necessary, especially regarding the guidance's application to sterile products.
click here